Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On Thursday 19 April, Oxford University will play host to an AIMday focused on Biomedical Imaging, which is at the heart of much of the clinical and biomedical research conducted at the University.

Following successful AIMdays focusing on Microscopy and Ageing, in April the Divisional Business Development Team will be running an AIMday in Biomedical Imaging, a broad topic which offers the opportunity to discuss the analysis, enhancement and display of images captured via x-ray, ultrasound, MRI, nuclear medicine and optical imaging technologies. A range of companies including GSK, GE Healthcare, Siemens, and Blue Earth Diagnostics are registered to attend, and it is a fantastic chance for researchers looking to network with industry and discuss relevant questions.

AIMdays are a concept which offer a unique way to facilitate interaction between industry and academia. Born at the University of Uppsala in 2008, they have increasingly gathered attention and use at universities across the globe looking to match researchers with industrial partners.

Interested industry partners are invited to submit questions around a certain topic. At the Microscopy AIMday run in Oxford last year, companies including Zeiss, Olympus, and Andor Technology submitted questions around imaging technologies to aid medical diagnostics, use of virtual reality to understand biological processes, and novel techniques for the future of microscopy research.

Academics then choose which of these questions they would like to answer, depending on their particular area of expertise. The AIMday algorithm designs a programme of one-hour sessions that matches industry partners and academics by their shared interests so that sessions can run in parallel, and interaction between industry and academics is maximised. 

Martin Kerr, Business Development Manager and organiser of the AIMday commented: 'AIMdays are a fantastic opportunity for researchers to spark new collaborations, build their networks, and get a fresh perspective on how their work could be translatable. It also offers early stage researchers exposure to the career paths offered by industry.' 

AIMday Biomedical Imaging takes place on Thu 19 April.  Academic registration opens on Mon 26 Feb – find out more and register.

If you would like to find out more about running an AIMday, please contact Martin Kerr

Similar stories

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.

University spinout PepGen awarded major financing to target Duchenne muscular dystrophy

Awards and Appointments General Innovation

PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.

Evox Therapeutics announces launch of strategic collaboration with the University of Oxford

General Innovation

Collaboration with world-renowned research centre to accelerate development of exosome therapies for rare diseases

BioEscalator’s resident biotech Base Genomics acquired by Exact Sciences

General Innovation

Oxford Sciences Innovation (OSI) recently announced the acquisition of its portfolio company, Base Genomics, by US-based early cancer diagnostic leaders, Exact Sciences, for $410m. The partnership will enable Base Genomics to significantly accelerate its clinical and commercial development here in Oxford, potentially unlocking a new era of preventative medicine and improved patient outcomes.